Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Completed · Phase 1/Phase 2
Conditions studied: Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of two different schedules of bortezomib when given together with pemetrexed disodium and to see how well they work in treating patients with advanced non-small cell lung cancer or other solid tumors.
Key facts
- Study ID
- NCT00389805
- Run by
- University of California, Davis
- People needed
- 27
- Starts
- 2005-03-01
- Expected to finish
- 2007-06-01
- Last updated by the study team
- 2018-10-31
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Davis Cancer Center — Sacramento, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.